Your browser doesn't support javascript.
loading
Mostrar: 20 | 50 | 100
Resultados 1 - 2 de 2
Filtrar
Mais filtros

Base de dados
Ano de publicação
Tipo de documento
Intervalo de ano de publicação
1.
J Pharmacol Exp Ther ; 300(2): 577-82, 2002 Feb.
Artigo em Inglês | MEDLINE | ID: mdl-11805219

RESUMO

Leukotriene (LT) B(4) is an inflammatory mediator that has been implicated in the pathogenesis of various diseases, including inflammatory bowel disease and psoriasis. As the rate-limiting step for LTB(4) production, LTA(4) hydrolase represents an attractive target for therapeutic agents that interfere with LTB(4) production. In the present study we evaluated a chemically novel compound designated SC-57461A (3-[methyl[3-[4-(phenylmethyl)phenoxy]propyl]amino]propanoic acid HCl) as an inhibitor of LTA(4) hydrolase. Pharmacological comparisons are made to its free acid SC-57461. SC-57461A is a potent competitive inhibitor of recombinant human LTA(4) hydrolase when either LTA(4) (IC(50) = 2.5 nM, K(i) = 23 nM) or peptide substrates (IC(50) = 27 nM) are used. In human whole blood, the IC(50) for calcium ionophore-induced LTB(4) production was 49 nM, indicative of good cell penetration. Whole blood production of the cyclooxygenase metabolite thromboxane B(2) was not affected. SC-57461A was also active in several other species, including mouse, rat, dog, and rhesus monkey. The data indicate that SC-57461A is a potent and selective inhibitor of LTA(4) hydrolase.


Assuntos
Inibidores Enzimáticos/farmacologia , Epóxido Hidrolases/antagonistas & inibidores , Antagonistas de Leucotrienos/farmacologia , beta-Alanina/análogos & derivados , beta-Alanina/farmacologia , Aminopeptidases/metabolismo , Animais , Ácido Araquidônico/metabolismo , Cromatografia Líquida de Alta Pressão , Cães , Eicosanoides/biossíntese , Eicosanoides/sangue , Ensaio de Imunoadsorção Enzimática , Epóxido Hidrolases/metabolismo , Humanos , Técnicas In Vitro , Ionóforos/farmacologia , Cinética , Leucotrieno A4/metabolismo , Macaca mulatta , Camundongos , Ratos , Proteínas Recombinantes/metabolismo , Especificidade da Espécie , Especificidade por Substrato
2.
J Pharmacol Exp Ther ; 300(2): 583-7, 2002 Feb.
Artigo em Inglês | MEDLINE | ID: mdl-11805220

RESUMO

Leukotriene (LT) A(4) hydrolase is a dual function enzyme that is essential for the conversion of LTA(4) to LTB(4) and also possesses an aminopeptidase activity. SC-57461A (3-[methyl[3-[4-phenylmethyl)phenoxy]propyl]amino]propanoic acid HCl) is a potent inhibitor of human recombinant LTA(4) hydrolase (epoxide hydrolase and aminopeptidase activities, K(i) values = 23 and 27 nM, respectively) as well as calcium ionophore-induced LTB(4) production in human whole blood (IC(50) = 49 nM). In the present study, we investigated its action in several animal models. Oral activity was evident from the ability of the compound to inhibit mouse ex vivo calcium ionophore-stimulated blood LTB(4) production with ED(50) values at 1.0 and 3.0 h of 0.2 and 0.8 mg/kg, respectively. A single oral dose of 10 mg/kg SC-57461A blocked mouse ex vivo LTB(4) production 67% at 18 h and 44% at 24 h, suggesting a long pharmacodynamic half-life. In a rat model of ionophore-induced peritoneal eicosanoid production, SC-57461 inhibited LTB(4) production in a dose-dependent manner (ED(50) = 0.3-1 mg/kg) without affecting LTC(4) or 6-keto-prostaglandin F(1alpha) production. Oral pretreatment with SC-57461 in a rat reversed passive dermal Arthus model blocked LTB(4) production with an ED(90) value of 3 to 10 mg/kg, demonstrating good penetration of drug into skin. Plasma level of intact SC-57461 (3 h after oral gavage dosing with 3 mg/kg) was 0.4 microg/ml, which corresponds to >80% inhibition of dermal LTB(4) production. Oral or topical pretreatment with SC-57461A 1 h before challenge with arachidonic acid blocked ear edema in the mouse. SC-57461A is a competitive, selective, and orally active inhibitor of LTA(4) hydrolase in vivo, making it useful to explore the contribution of LTB(4) to a number of inflammatory diseases.


Assuntos
Inibidores Enzimáticos/farmacologia , Epóxido Hidrolases/antagonistas & inibidores , Hidroxiureia/análogos & derivados , Leucotrieno A4/biossíntese , Antagonistas de Leucotrienos/farmacologia , beta-Alanina/análogos & derivados , beta-Alanina/farmacologia , Administração Oral , Administração Tópica , Animais , Reação de Arthus/patologia , Dermatite/metabolismo , Edema/induzido quimicamente , Edema/metabolismo , Edema/prevenção & controle , Eicosanoides/biossíntese , Eicosanoides/sangue , Inibidores Enzimáticos/farmacocinética , Hidroxiureia/farmacologia , Técnicas In Vitro , Antagonistas de Leucotrienos/farmacocinética , Inibidores de Lipoxigenase/farmacologia , Camundongos , Peritônio/efeitos dos fármacos , Peritônio/metabolismo , Ratos , Pele/efeitos dos fármacos , Pele/metabolismo , beta-Alanina/farmacocinética
SELEÇÃO DE REFERÊNCIAS
DETALHE DA PESQUISA